Maxime Dely: Therapeutic Apheresis – How Do You Know When You Can’t Wait Any Longer?
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Therapeutic Apheresis: How do you know when you can’t wait any longer?
3 clinical criteria to decide on Therapeutic Apheresis
Therapeutic apheresis is neither an automatic reflex nor a last-resort treatment by default. The right indication relies on a structured clinical reasoning, which can be summarized into three key criteria.
1. A clearly identifiable circulating pathogenic target
Apheresis makes sense when the disease mechanism involves a blood-borne factor that can be mechanically removed:
– autoantibodies (TTP, myasthenia gravis, Goodpasture syndrome)
– immune complexes (severe lupus)
– abnormal cells (leukostasis in acute leukemias)
– lipoproteins (homozygous familial hypercholesterolemia)
Without a clearly identified circulating target, the expected benefit becomes questionable.
2. Acute or rapidly progressive clinical severity
Myasthenic crisis with respiratory failure, thrombotic thrombocytopenic purpura, progressive Guillain–Barré syndrome, antibody-mediated graft rejection…
In these situations, apheresis is a life-saving or organ-saving emergency intervention.
3. A mismatch between clinical urgency and the onset of action of standard therapies
Immunosuppressive drugs, IVIg, or chemotherapy may be effective — but sometimes too slow.
Therapeutic apheresis allows an immediate reduction of the pathogenic burden, stabilizing the patient and creating a therapeutic window.
Deciding on apheresis is not about ticking boxes on a list of indications. It is about integrating pathophysiology, clinical severity, and timing, through close multidisciplinary collaboration.
When properly indicated, apheresis is not a technical luxury — it is a strategic clinical tool.”

Find more posts featuring Maxime Dely on Hemostasis Today.
-
Nov 15, 2026, 23:44Pablo César Spada: Prevention of Venous Thromboembolism After Total Hip or Knee Replacement
-
Nov 15, 2026, 23:30Eshal Amir: Factor XI Inhibitors in AFib and Aortic Mortality Trends
-
Nov 15, 2026, 23:19Hamza Bashir: Adding Endovascular Therapy to Anticoagulation Cuts Moderate-to-Severe PTS in Half
-
Nov 15, 2026, 23:06Lanre Tunji-Ajayi: 2 Days of Deliberative Dialogue Hosted by the Network of Rare Blood Disorder Organizations
-
Nov 15, 2026, 23:00Fanny Delettre: Looking Back at Volunteer Blood Donor Friends Day
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines